Biopharma News
Advanced Scientifics and Chemic Laboratories Announce Joint Cooperation Agreement
Advanced Scientifics and Chemic Laboratories enter a three-year joint cooperation agreement to collaborate on product development projects.
AstraZeneca and MRC Laboratory of Molecular Biology Launch Joint Research Fund
AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology to fund a range of pre-clinical research projects.
KBI Biopharma Acquires Merck's Biologics Operations
KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.
Shire Acquires Lumena Pharmaceuticals
Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.
Cumberland Pharmaceuticals and Gloria Pharmaceuticals Announce R&D Investment
Cumberland Pharmaceuticals and Gloria Pharmaceuticals invest $1 million each in Cumberland Emerging Technologies.
Boehringer Ingelheim and Connexios Life Sciences Enter Agreement for AMPK Activators
Boehringer Ingelheim and Connexios Life Sciences announce global research collaboration agreement for AMPK agonists.
Agenus Collaborates with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies
Agenus and Merck work together to advance immune-oncology programs.
Allergy Therapeutics' Worthing Facility Receives Certificate of GMP Compliance
Allergy Therapeutics announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.
Bristol-Myers Squibb Acquires iPierian
BMS acquisition of iPierian advances BMS' pursuit of therapeutics for genetically defined diseases.
Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement
Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.
Eli Lilly's Cyramza Receives FDA Approval for Treatment of Advanced Gastric Cancer
Lilly1s Cyramza is the first FDA-approved treatment for advanced gastric cancer after prior chemotherapy.
Aastrom Biosciences Acquires Sanofi's Cell Therapy and Regenerative Medicine Business
Aastrom Biosciences will acquire Sanofi's CTRM business for $6.5 million.
Novartis's Bexsero Receives FDA Breakthrough Therapy Designation
Novartis receives FDA breakthrough therapy designation for Bexsero, a meningitis B vaccine.
PolyTherics and MacroGenics Extend ADC Collaboration
ThioBridge linker technology to attach different payloads to a range of antibodies
uniQure Announces Management Changes
uniQure appoints a new COO and vice president, Medical affairs.
Lilly To Release Data Targeting Key Cancer Pathways At AACR 2014
Eli Lilly will present early-stage data regarding cancer therapies at AACR 2014.
Sun Pharma to Acquire Ranbaxy
Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.
A New Plant Biotech Approach for Efficient Production of Pharmaceutical Compound
European scientists have discovered a method to improve the efficiency of the pharmaceutical production through plant biotechnology.
Recurrent Head and Neck Tumors Could be Vulnerable to Cancer Drug
New research finds that recurrent head and neck tumors have gene mutations that could be vulnerable to the cancer drug dasatinib.
Immunovaccine Presents New Cancer Vaccine Data at AACR
Immunovaccine reports enhanced cancer vaccine combination therapies at 2014 AACR Annual Meeting.
Genzyme to Resubmit Lemtrada Application for FDA Review
Sanofi and Genzyme to resubmit FDA application for approval of Lemtrada, for the treatment of relapsing forms of multiple sclerosis.
Novartis and Malaria No More Campaign Provide Antimalarial Treatments in Zambia
Novartis delivers 2 million treatments of its pediatric antimalarial to Zambia in collaboration with Malaria No More's Power of One campaign.
Baxter to Split Into Biopharmaceuticals and Medical Products Companies
Baxter announces plans to split into two independent companies by mid-2015.
XstalBio Launches Vaccine Analysis Service
XstalBio Analytics' approach to vaccine analysis and formulation is aimed at understanding the antigen– adjuvant interaction.
FDA approves Novartis' Xolair for Rare Skin Disease
FDA approves Xolair (omalizumab) for the treatment of a rare skin disease known as chronic idiopathic urticarial.
Cobra Biologics and BioCancell Collaborate on Cancer Therapy Drug
Cobra Biologics and BioCancell announce an agreement to manufacture BioCancell's BC-821 cancer drug.
Novartis Recognizes Rare Disease Day
Novartis calls for more research to understand and find treatments for rare disease.
Debiopharm Group to Acquire Affinium Antibiotic Clinical Assets
Debiopharm acquires Affinium's clinical and preclinical assets and its technology platform.
PharmaCell to Purchase Cell Therapy Production Facility from TiGenix
PharmaCell enters an agreement purchase TiGenix therapy production facility.
